Switch theme
Sign up to access all valuation multiples
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
1992
288
LTM Revenue $116M
LTM EBITDA $9.1M
$132M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Anika Therapeutics has a last 12-month revenue (LTM) of $116M and a last 12-month EBITDA of $9.1M.
In the most recent fiscal year, Anika Therapeutics achieved revenue of $120M and an EBITDA of $3.0M.
Anika Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Anika Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $116M | XXX | $120M | XXX | XXX | XXX |
| Gross Profit | $59.1M | XXX | $76.0M | XXX | XXX | XXX |
| Gross Margin | 51% | XXX | 63% | XXX | XXX | XXX |
| EBITDA | $9.1M | XXX | $3.0M | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 3% | XXX | XXX | XXX |
| EBIT | -$18.8M | XXX | -$5.1M | XXX | XXX | XXX |
| EBIT Margin | -16% | XXX | -4% | XXX | XXX | XXX |
| Net Profit | -$39.4M | XXX | -$56.4M | XXX | XXX | XXX |
| Net Margin | -34% | XXX | -47% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Anika Therapeutics's stock price is $11.
Anika Therapeutics has current market cap of $160M, and EV of $132M.
See Anika Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $132M | $160M | XXX | XXX | XXX | XXX | $-0.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Anika Therapeutics has market cap of $160M and EV of $132M.
Anika Therapeutics's trades at 1.1x EV/Revenue multiple, and 43.8x EV/EBITDA.
Equity research analysts estimate Anika Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Anika Therapeutics has a P/E ratio of -4.1x.
See valuation multiples for Anika Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $160M | XXX | $160M | XXX | XXX | XXX |
| EV (current) | $132M | XXX | $132M | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | 14.5x | XXX | 43.8x | XXX | XXX | XXX |
| EV/EBIT | -7.0x | XXX | -25.9x | XXX | XXX | XXX |
| EV/Gross Profit | 2.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.1x | XXX | -2.8x | XXX | XXX | XXX |
| EV/FCF | -41.4x | XXX | -45.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAnika Therapeutics's last 12 month revenue growth is -1%
Anika Therapeutics's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
Anika Therapeutics's rule of 40 is -8% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Anika Therapeutics's rule of X is 5% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Anika Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Growth | -82% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -8% | XXX | 1% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 5% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 68% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Anika Therapeutics acquired XXX companies to date.
Last acquisition by Anika Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Anika Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Anika Therapeutics founded? | Anika Therapeutics was founded in 1992. |
| Where is Anika Therapeutics headquartered? | Anika Therapeutics is headquartered in United States of America. |
| How many employees does Anika Therapeutics have? | As of today, Anika Therapeutics has 288 employees. |
| Who is the CEO of Anika Therapeutics? | Anika Therapeutics's CEO is Dr. Cheryl R. Blanchard, PhD. |
| Is Anika Therapeutics publicy listed? | Yes, Anika Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Anika Therapeutics? | Anika Therapeutics trades under ANIK ticker. |
| When did Anika Therapeutics go public? | Anika Therapeutics went public in 1993. |
| Who are competitors of Anika Therapeutics? | Similar companies to Anika Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Anika Therapeutics? | Anika Therapeutics's current market cap is $160M |
| What is the current revenue of Anika Therapeutics? | Anika Therapeutics's last 12 months revenue is $116M. |
| What is the current revenue growth of Anika Therapeutics? | Anika Therapeutics revenue growth (NTM/LTM) is -1%. |
| What is the current EV/Revenue multiple of Anika Therapeutics? | Current revenue multiple of Anika Therapeutics is 1.1x. |
| Is Anika Therapeutics profitable? | Yes, Anika Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Anika Therapeutics? | Anika Therapeutics's last 12 months EBITDA is $9.1M. |
| What is Anika Therapeutics's EBITDA margin? | Anika Therapeutics's last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of Anika Therapeutics? | Current EBITDA multiple of Anika Therapeutics is 14.5x. |
| What is the current FCF of Anika Therapeutics? | Anika Therapeutics's last 12 months FCF is -$3.2M. |
| What is Anika Therapeutics's FCF margin? | Anika Therapeutics's last 12 months FCF margin is -3%. |
| What is the current EV/FCF multiple of Anika Therapeutics? | Current FCF multiple of Anika Therapeutics is -41.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
